Ripac New Build – Latest news

Next milestone in the Ripac-Labor New Build project: ‘the laying of the foundation stone’

Last week, the board members of Dopharma B.V., together with Heiko Rüdiger (CEO RIPAC-LABOR GmbH-Labor), [...]

Dopharma and Ripac-Labor announce Ground-breaking Ceremony for new Autogenous Vaccine Production Facility in Potsdam

Raamsdonksveer, Netherlands / Potsdam, Germany, 28 February 2025 – The Dopharma Group and its fully owned [...]

Ripac New Build – Media Gallery

Ground-breaking Ceremony

Friday, February 28, 2025

Laying of the foundation stone

Wednesday, June 18, 2025

Ripac New Build Newsletter

Follow the journey of the Ripac New Build project.
Name(Required)
Newsletter consent(Required)

Follow on LinkedIn

More information

Ripac-Labor GmbH, a fully owned subsidiary of Dopharma International B.V., specializes in veterinary services and the production of autogenous vaccines for livestock. These customized vaccines provide targeted protection against farm-specific pathogens, offering a crucial tool for disease prevention and control. The expansion of Ripac-Labor’s production capabilities further strengthens the Dopharma group’s position in the European veterinary market.

The company currently employs 48 academic specialists, experienced laboratory technicians, and other well-trained staff.

Dopharma is a family-owned pharmaceutical company dedicated to producing and supplying high-quality veterinary pharmaceuticals for livestock since 1969. With 95% of its veterinary pharmaceuticals manufactured in-house at its GMP-certified production facilities, Dopharma ensures strict quality control and continuous innovation. The company’s mission is to provide smart, science-driven solutions that support the health and productivity of livestock worldwide.

www.dopharma.com

For media inquiries which are not available on this site, please contact [email protected].